Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction

Kundi, Harun; Balun, Ahmet; Çiçekçioğlu, Hülya; Karayiğit, Orhan; Topçuoğlu, Canan; Kılınçkaya, Muhammed Fevzi; Kızıltunç, Emrullah; Çetın, Mustafa; Örnek, Ender

doi:10.1177/0003319716646932

Cited by 43 publications

(48 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown the association between the endocan levels and CAD, AMI, newly diagnosed hypertension, and coronary ectasia (9, 10, 31, 32). Kundi et al (10) reported that the admission of high endocan levels is an independent predictor of in-hospital mortality and an increased SYNTAX score in patients with STEMI. Xiong et al (33) investigated the relationship between endocan levels and the presence and severity of CAD in patients with hypertension, and they found an independent correlation between endocan levels and the presence and severity of CAD.…”

Section: Discussionmentioning

confidence: 99%

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

et al. 2019

View full text Add to dashboard Cite

Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction Introduction Myocardial infarction remains the leading cause of morbidity and mortality worldwide. In 2015, more than 8.75 million people lost their lives due to coronary artery disease (CAD), accounting for 15.5% of all deaths (1). Endothelial dysfunction, inflammation, and disruption-rupture of atherosclerotic plaques play a critical role in the pathogenesis of atherosclerosis and acute myocardial infarction (AMI) (2-5). Endothelial specific molecule-1 (ESM-1) or endocan, is a soluble dermatan sulfate proteoglycan, secreted and expressed by human vascular endothelial cells (6). The elevated levels of the endocan in patients with tumor progression or in patients with sepsis suggest that endocan may be a probable biomarker for endothelial dysfunction or endothelial activation (7, 8). A previous study showed that endocan levels have been significantly increased in patients with acute coronary syndrome (ACS) (9). In another study, admission endocan levels were found to be associated with in-hospital mortality and the CAD severity index in patients with ST segment elevation myocardial infarction (STEMI) (10). Adipose tissue is an active endocrine organ and regulates energy homeostasis and metabolism by communicating with Objective: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI). Methods: Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy. Results: Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03-143.69) pg/mL to 99.22 (78.30-122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28-165.22) pg/mL to 93.40 (70.48-115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00-525.95) ng/mL to 135.00 (105.95-225.65) ng/ mL with atorvastatin 80 mg and from 309.95 (168.87-701.27) ng/mL to 121.25 (86.60-212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups]. Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00 (13.10-22.25) ng/mL to 19.30 (15.25-23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82-23.82) ng/mL to 16.60 (10.60-20.15) ng/ mL with rosuvastatin 4...

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Previous studies examined the association of endocan with heart disease. [13,26] In a study of 164 patients, Wang et al [27] reported that serum levels of endocan were correlated with the presence and severity of coronary artery disease. Balta et al [13] reported that vascular inflammation played an important role in the pathophysiology of hypertension and that the increased level of endocan may be indicative of untreated hypertension.…”

Section: Discussionmentioning

confidence: 99%

“…Similar studies reported that endocan can be used as a biomarker in the diagnosis and follow-up of cardiovascular diseases. [13,26] They also suggested that endocan induced endothelial activation or dysfunction in endothelium-derived diseases and that it may serve as a biomarker of inflammation in diseases of vascular origin. [13][14][15] Although many studies concluded that an increase in the serum level of endocan was a sign of a worsening disease, there is discord in the literature on this topic.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Therapeutic Effect of Resveratrol in Heart Failure Following Blunt Chest Trauma in Rats and the Potential Role of Endokan as a Biomarker of Inflammation

Torun

Tütüncü

2018

Ulus Travma Acil Cerrahi Derg

View full text Add to dashboard Cite

BACKGROUND: The present study investigated the therapeutic effect of resveratrol on cardiac injury resulting from blunt chest trauma and the utility of endocan as a biomarker of the inflammation process using rats. METHODS: The rats were randomly divided into the following four groups (n=7 in each group): a control group (no treatment or trauma); trauma-induced group (trauma group); resveratrol group (resveratrol 0.3 mg/kg administered via the intraperitoneal [i.p.] route group); and resveratrol + trauma group (resveratrol 0.3 mg/kg administered via the i.p. route 1 hour prior to the induction of trauma). RESULTS: The immunoreactivity of tumor necrosis factor-α and inducible nitric oxide synthase in the trauma group was increased, whereas the reaction intensity in resveratrol + trauma group was deceased. The mean endocan values of the differed between the groups (p<0.001). The mean endocan value in the resveratrol + trauma group was higher than that of the other groups. CONCLUSION: Resveratrol exhibited anti-inflammatory and antioxidant effects in lung injury after blunt chest trauma and contributed favorably to the treatment process. We believe that there is a need for further studies on the clinical use of endocan as a biomarker of inflammation in cardiac injury after blunt chest trauma.

show abstract

“…Endocan was increased by many inflammatory diseases and used as a biomarker for ongoing vascular inflammation and endothelial dysfunction. Increased serum endocan levels were observed in various clinical settings characterized by endothelial dysfunction such as hypertension (21), obstructive coronary artery disease (22), acute coronary syndrome (9,23), and diabetes mellitus (24,25). In the present study, serum endocan level was analyzed in the case of lead exposure, and endothelial dysfunction as main link between lead exposure and diastolic dysfunction has been evaluated by serum endocan level for the first time.…”

Section: Characteristicsmentioning

confidence: 90%

Serum endocan level and diastolic functions in the case of lead exposure

Karakulak¹,

Gündüzöz²,

Bal³

et al. 2019

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction in vasculature. Endocan, as a novel indicator of endothelial dysfunction, has been used for cardiovascular diseases. This study investigated the relationship between lead exposure, endocan levels, and diastolic functions. Materials and methods: A total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthy controls were enrolled. All participants underwent transthoracic echocardiography. Blood lead and serum endocan levels were analyzed. Results: Baseline demographic and clinical characteristics were found to be similar between groups. Median blood lead (32 vs 1.5 µg/dL, P < 0.001) and serum endocan levels (67 vs 57.1 pg/mL, P = 0.02) were significantly higher in the lead-exposed group. Serum endocan level showed a positive correlation with blood lead levels (r = 0.404, P = 0.003) in lead-exposed workers. Serum endocan level was an independent risk factor for increased E/E' ratio (β = 0.704, P = 0.002) and left atrial volume index (β = 1.158, P = 0.011) and higher level of lead in blood was an independent risk factor for increased E wave (β = 8.004, P = 0.022) in lead-exposed workers. Conclusion: Worsened diastolic functions may be seen in the course of lead exposure. Due to sharing a similar mechanism, a higher serum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.

show abstract

Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction

Cited by 43 publications

References 27 publications

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

Assessment of the Therapeutic Effect of Resveratrol in Heart Failure Following Blunt Chest Trauma in Rats and the Potential Role of Endokan as a Biomarker of Inflammation

Serum endocan level and diastolic functions in the case of lead exposure

Contact Info

Product

Resources

About